牛牛AI助手已提取核心信息
AbbVie Inc. has reported preliminary financial results for the fourth quarter of 2023, including an acquired IPR&D and milestones expense of $282 million on a pre-tax basis. This expense is expected to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.15. The results for the quarter ending December 31, 2023, are not yet finalized and are subject to financial statement closing procedures. AbbVie has stated that there is no assurance that the final results will not differ from these preliminary estimates. The company does not forecast acquired IPR&D and milestones expense due to the uncertainty of future transactions. AbbVie's full-year 2023 adjusted diluted earnings per share guidance, including the impact of the fourth quarter expense, is...Show More
AbbVie Inc. has reported preliminary financial results for the fourth quarter of 2023, including an acquired IPR&D and milestones expense of $282 million on a pre-tax basis. This expense is expected to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.15. The results for the quarter ending December 31, 2023, are not yet finalized and are subject to financial statement closing procedures. AbbVie has stated that there is no assurance that the final results will not differ from these preliminary estimates. The company does not forecast acquired IPR&D and milestones expense due to the uncertainty of future transactions. AbbVie's full-year 2023 adjusted diluted earnings per share guidance, including the impact of the fourth quarter expense, is projected to be between $11.04 and $11.08. The guidance for the fourth quarter adjusted diluted earnings per share, also including this expense, is estimated to be between $2.72 and $2.76. The company has furnished this information as Exhibit 99.1 to the Current Report on Form 8-K. AbbVie has also cautioned that forward-looking statements in the report are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
艾伯维公司公布了2023年第四季度的初步财务业绩，包括收购的IPR&D和税前2.82亿美元的里程碑支出。预计该支出将对GAAP和调整后的非GAAP摊薄后每股收益产生0.15美元的不利影响。截至2023年12月31日的季度业绩尚未最终确定，须遵守财务报表结算程序。艾伯维表示，无法保证最终结果不会与这些初步估计有所不同。由于未来交易的不确定性，该公司不预测收购的知识产权研发和里程碑费用。艾伯维2023年全年调整后的摊薄后每股收益指引，包括第四季度支出的影响，预计将在11.04美元至11.08美元之间。第四季度调整后的摊薄后每股收益（包括这笔支出）的预期在2.72美元至2.76美元之间。该公司已将这些信息作为当前8-K表报告的附录99.1提供。艾伯维还警告说，报告中的前瞻性陈述存在风险和不确定性，可能导致实际业绩与明示或暗示的结果存在重大差异。
艾伯维公司公布了2023年第四季度的初步财务业绩，包括收购的IPR&D和税前2.82亿美元的里程碑支出。预计该支出将对GAAP和调整后的非GAAP摊薄后每股收益产生0.15美元的不利影响。截至2023年12月31日的季度业绩尚未最终确定，须遵守财务报表结算程序。艾伯维表示，无法保证最终结果不会与这些初步估计有所不同。由于未来交易的不确定性，该公司不预测收购的知识产权研发和里程碑费用。艾伯维2023年全年调整后的摊薄后每股收益指引，包括第四季度支出的影响，预计将在11.04美元至11.08美元之间。第四季度调整后的摊薄后每股收益（包括这笔支出）的预期在2.72美元至2.76美元之间。该公司已将这些信息作为当前8-K表报告的附录99.1提供。艾伯维还警告说，报告中的前瞻性陈述存在风险和不确定性，可能导致实际业绩与明示或暗示的结果存在重大差异。
有用
没用